Anabasis is a private, Milan based, biopharmaceutical company dedicated to the development
of innovative therapies for the eye.
The initial focus is NGF (Nerve Growth Factor) for the treatment of diseases affecting
both the anterior part of the eye, such as neurotrophic keratitis (NK) and dry eye,
as well as the posterior part of the eye such as glaucoma. These diseases can lead
to severe vision loss and blindness.
In January 2011
Italian leading biopharmaceutical company, became Anabasis’s parent company by acquiring
49% of its shares. Furthermore, in the same year, Dompé acquired the worldwide
rights for the development and the commercialization of NGF for NK. This agreement
provided Anabasis with the resources and the expertise needed to significantly grow
the business and demonstrate efficacy of products through regulatory clinical development.
In February 2012 Dompé Group became the sole shareholder of Anabasis by acquiring
the remaining 51% of its share capital.
Dompé’s headquarters now serve as the head office for Anabasis pharmaceutical operations.
this website is going to be shortly decommissioned.
Any further information regarding R&D activities in ophthalmology can be found on www.dompe.com/ophthalmology.